A Study to Evaluate the Preventive Effect of Purastat, a novel hemostatic peptide solution, to prevent bleeding after endoscopic submucosal dissection of a gastric tumor

A Study to Evaluate the Preventive Effect of Purastat, a novel hemostatic peptide solution, to prevent bleeding after endoscopic submucosal dissection of a gastric tumor - A Study to Evaluate the Preventive Effect of Purastat, a novel hemostatic peptide solution, to prevent bleeding after endoscopic submucosal dissection of a gastric tumor

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000053481

Enrollment

100

Registered

2024-01-30

Start date

2022-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric tumor

Interventions

PuraStat (1 mL) was used to stop bleeding during ESD, and after ESD, bleeding from the remaining blood vessels in the post-ESD ulcer was stopped by initiating coagulation using hemostatic forceps. Sub

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: From May 2022 to March 2023, patients who underwent ESD for gastric diseases at our hospital

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Post-ESD bleeding	—

Secondary

Measure	Time frame
The duration from ESD to the onset of post-ESD bleeding and adverse events associated with PuraStat administration.	—

Countries

Japan

Contacts

Public ContactKuniyo Gomi

Showa University Fujigaoka Hospital Department of Gastroenterology

kunxaqua@med.showa-u.ac.jp0459711151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026